Business
Access to pioneering research in Bordeaux France
Access to pioneering research in Bordeaux France.
About this update from Immupharma Plc
[{"type":"text","content":"\n \nRNS Number : 6918K Immupharma PLC 27 June 2014 \n\n \n\n\n\n\nFOR IMMEDIATE RELEASE\n\n\n 27 JUNE 2014\n\n\n\n\n \n \n \nImmuPharma to access pioneering research in the Bordeaux region of France\n \nImmuPharma PLC (LSE:IMM), (\"ImmuPharma\" or the \"Company\"), the specialist drug discovery and development company, is delighted to provide further details on its activities in the Bordeaux region of France, working closely with one of its key collaborators at the CNRS*, ImmuPharma's longstanding research partner, accessing novel drug research in the area of peptides.\nOne key relationship for Bordeaux is with the Institut Européen de Chimie et Biologie (IECB) an international and interdisciplinary research team incubator, placed under the joint authority of the CNRS, INSERM (Institut National de la Santé et de la Recherche Médicale)* and the University of Bordeaux*.\nThrough its network, IECB hosts 15 international and multi-disciplinary research teams among them being the CNRS team of Dr Gilles Guichard, one of the scientific founders of ImmuPharma, and a leading researcher in peptides. Additionally, one of ImmuPharma's fully owned subsidiaries, 'UREKA'a pharmaceutical R&D unit, has its new internal research team based at the IECB.\n \nImmuPharma recently announced at its Preliminary Results that the long standing collaboration with the CNRS under Dr. Gilles Guichard and UREKA had resulted in the filing of a new co-owned patent controlling a breakthrough peptide technology called 'Urelix', allowing in essence to mimic long natural peptides especially in the configuration used to bind their receptor and improve their stability to enzymatic degradation (breakdown of peptides into aminoacids) as well as greater efficacy. The first therapeutic area being targeted is diabetes (with GLP1* and GIP* as targets). Blocking the protein/protein interaction could also be used in fighting viruses (blocking virus entry into cells) which could be further investigated. The potential of this technology is substantial and diverse and is one of the key reasons UREKA has established its own research team (some provided from Dr. Guichard's laboratory or from other prestigious Universities such as ETH Zurich) and working in close collaboration with Dr. Guichard and his...